Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.42
-0.49 (-2.59%)
At close: Jul 14, 2026, 4:00 PM EDT
18.56
+0.14 (0.76%)
After-hours: Jul 14, 2026, 6:05 PM EDT
Avalo Therapeutics Employees
Avalo Therapeutics had 33 employees as of December 31, 2025. The number of employees increased by 10 or 43.48% compared to the previous year.
Employees
33
Change (1Y)
10
Growth (1Y)
43.48%
Revenue / Employee
$1,788
Profits / Employee
-$2,567,879
Market Cap
968.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 10 | 43.48% | 33 | 0 |
| Dec 31, 2024 | 23 | 4 | 21.05% | 23 | 0 |
| Dec 31, 2023 | 19 | -1 | -5.00% | 19 | 0 |
| Dec 31, 2022 | 20 | -24 | -54.55% | 20 | 0 |
| Dec 31, 2021 | 44 | 13 | 41.94% | 42 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Phathom Pharmaceuticals | 371 |
| Kura Oncology | 260 |
| Geron | 258 |
| DBV Technologies | 161 |
| Olema Pharmaceuticals | 137 |
| Solid Biosciences | 121 |
| Janux Therapeutics | 108 |
AVTX News
- 7 days ago - Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum - GlobeNewsWire
- 8 days ago - Avalo Therapeutics initiated with an Outperform at Leerink - TheFly
- 18 days ago - Avalo Therapeutics to join Russell 2000, Russell 3000 - TheFly
- 18 days ago - Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 21 days ago - Avalo Therapeutics Appoints Ron Philip to Board of Directors - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics advances AVTX-010 - TheFly
- 4 weeks ago - Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics initiated with a Buy at BofA - TheFly